Jitka Koblihova

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

Klára Šrůtová, Nikola Čuřík, Pavel Burda et al. · Haematologica · 2018 · 45 citations · Full text

Medicine, Molecular Biology, Oncology +17

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

Kateřina Machová Poláková, Hana Žižková, Jan Zuna et al. · Leukemia · 2020 · 30 citations · Full text

Medicine, Molecular Biology, Oncology +15

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Matthew Salmon, Helen E. White, Hana Žižková et al. · Leukemia · 2022 · 20 citations · Full text

Medicine, Hematology, Oncology +11

Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells

Václava Polívková, Adela Benesova, Hana Žižková et al. · Leukemia · 2021 · 10 citations

Life Sciences, Molecular Biology, Oncology +16

Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining

Nikola Čuřík, Václava Polívková, Pavel Burda et al. · Frontiers in Oncology · 2021 · 10 citations · Full text

Medicine, Molecular Biology, Oncology +14